全文获取类型
收费全文 | 22985篇 |
免费 | 1958篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 292篇 |
儿科学 | 736篇 |
妇产科学 | 558篇 |
基础医学 | 2917篇 |
口腔科学 | 513篇 |
临床医学 | 1901篇 |
内科学 | 5184篇 |
皮肤病学 | 689篇 |
神经病学 | 1559篇 |
特种医学 | 917篇 |
外国民族医学 | 7篇 |
外科学 | 3908篇 |
综合类 | 225篇 |
一般理论 | 2篇 |
预防医学 | 1651篇 |
眼科学 | 533篇 |
药学 | 1618篇 |
中国医学 | 96篇 |
肿瘤学 | 1750篇 |
出版年
2023年 | 189篇 |
2022年 | 509篇 |
2021年 | 853篇 |
2020年 | 583篇 |
2019年 | 908篇 |
2018年 | 1123篇 |
2017年 | 777篇 |
2016年 | 818篇 |
2015年 | 711篇 |
2014年 | 1027篇 |
2013年 | 1384篇 |
2012年 | 1733篇 |
2011年 | 1763篇 |
2010年 | 1119篇 |
2009年 | 1031篇 |
2008年 | 1264篇 |
2007年 | 1233篇 |
2006年 | 1186篇 |
2005年 | 1011篇 |
2004年 | 921篇 |
2003年 | 732篇 |
2002年 | 699篇 |
2001年 | 435篇 |
2000年 | 437篇 |
1999年 | 333篇 |
1998年 | 165篇 |
1997年 | 135篇 |
1996年 | 129篇 |
1995年 | 94篇 |
1994年 | 82篇 |
1993年 | 62篇 |
1992年 | 107篇 |
1991年 | 117篇 |
1990年 | 84篇 |
1989年 | 87篇 |
1988年 | 87篇 |
1987年 | 75篇 |
1986年 | 62篇 |
1985年 | 59篇 |
1984年 | 105篇 |
1983年 | 91篇 |
1982年 | 65篇 |
1981年 | 48篇 |
1980年 | 59篇 |
1979年 | 68篇 |
1978年 | 53篇 |
1977年 | 49篇 |
1976年 | 50篇 |
1975年 | 47篇 |
1974年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献4.
5.
ABSTRACTScreening rates for trauma are low in health care settings. We examined the association between health care providers’ (HCPs) experience of physical or sexual trauma and their screening of female patients for trauma. HCPs at an urban academic medical institution were surveyed from September through November 2016. The Brief Trauma (BTQ) and Sexual and Physical Abuse History Questionnaires (SPAHQ) assessed their own experiences of trauma. The Screening Practices Questionnaire (SPQ) assessed HCPs trauma screening. Multiple regression analyses were performed. Among 212 respondents aged 22–67 years, most were female (78.3%) and white (76.1%). Nurses (41.0%) were the largest occupational group. Overall, 85.8% reported having experienced trauma. No significant difference was observed in median SPQ scores between HCPs who had experienced trauma (3.88 [Interquartile Range (IQR) 3.44–4.31]) and those who had not (4.00 [IQR 3.47–4.33], p = .645). In an adjusted model, screening policy awareness and having an obstetrics & gynecology or psychiatry specialty were associated with higher SPQ scores (p < .001). The prevalence of trauma experience in this sample was high, but not associated with screening. Screening policy awareness and practice specialty were associated with screening. HCP factors associated with greater trauma screening should be explored. 相似文献
6.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
7.
8.
9.
David M Dohan Joseph Choukroun Antoine Diss Steve L Dohan Anthony J J Dohan Jaafar Mouhyi Bruno Gogly 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2006,101(3):e37-e44
Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates geared to simplified preparation without biochemical blood handling. In this initial article, we describe the conceptual and technical evolution from fibrin glues to platelet concentrates. This retrospective analysis is necessary for the understanding of fibrin technologies and the evaluation of the biochemical properties of 3 generations of surgical additives, respectively fibrin adhesives, concentrated platelet-rich plasma (cPRP) and PRF. Indeed, the 3-dimensional fibrin architecture is deeply dependent on artificial clinical polymerization processes, such as massive bovine thrombin addition. Currently, the slow polymerization during PRF preparation seems to generate a fibrin network very similar to the natural one. Such a network leads to a more efficient cell migration and proliferation and thus cicatrization. 相似文献
10.
Maren T Scheuner William C Whitworth Henraya McGruder Paula W Yoon Muin J Khoury 《Genetics in medicine》2006,8(8):525-531
PURPOSE: We examined the performance of a familial risk assessment method that stratifies risk for early-onset coronary heart disease by considering the number of relatives with coronary disease, degree of relationship, lineage, and age at diagnosis. METHODS: By using data from the HealthStyles 2003 survey, we assessed the associations between familial risk and early-onset coronary heart disease, diabetes, hypercholesterolemia, hypertension, and obesity. By using area under the curve statistics, we evaluated the discriminatory ability of various risk assessment models. RESULTS: Of 4,035 respondents, 60% were female and 72% were white, with a mean age of 48.8 years. After adjustment for demographics, strong and moderate risk were significantly associated with approximately a five- and twofold risk of early-onset coronary disease, respectively. After adjustment for demographics and personal history of cardiovascular disease, strong familial risk was also significantly associated with diabetes, hypercholesterolemia, hypertension, and obesity. A risk assessment model that included familial risk, demographics, and personal history of diabetes, hypercholesterolemia, hypertension, and obesity was most optimal with an area under the curve statistic of 87.2% CONCLUSIONS: Familial risk assessment can stratify risk for early-onset coronary heart disease. Several conditions associated with increased familial risk can be prevented. These results have important implications for risk assessment and risk-reducing interventions. 相似文献